Realm Therapeutics to Present at BIO-Europe® 2017

MALVERN, Pa., Nov. 2, 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the 23rd annual BIO-Europe®, a global life sciences partnering event, on Wednesday, November 8, 2017 at 12:15 p.m. CET at the CityCube Berlin in Berlin, Germany.

Mr. Martin will review the Company's two lead drug development programs: PR022 for Atopic Dermatitis and PR013 for Allergic Conjunctivitis. The Company remains on track to initiate Phase 2 clinical studies for both PR022 and PR013 by the end of 2017. An updated copy of Realm's corporate presentation is available on the Company's website at www.realmtx.com.

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.